Roche is entering the fight against obesity with petrelintide, which plans to enter Phase 3 clinical trials this quarter[1]. According to early clinical data, petrelintide offers comparable weight loss to GLP-1 drugs, but with better tolerability and preservation of muscle mass[1]. The drug works by increasing the feeling of satiety and slowing down gastric emptying[1]. As monotherapy, it targets 15-20% weight loss in phase 3 clinical trials[1]. Roche has stockpiled $550 million worth of the drug for the global launch of the product[1]. Approval for the treatment of obesity is planned this year, for the treatment of diabetes in 2026[1]. Results from phase 2b clinical trials are expected in the summer of 2026, with phase 3 expected to follow immediately thereafter[1].